|Other Names||Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha isoform, Medium tumor antigen-associated 61 kDa protein, PP2A subunit A isoform PR65-alpha, PP2A subunit A isoform R1-alpha, PPP2R1A|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1943a was selected from the N-term region of human PPP2R1A. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||The PR65 subunit of protein phosphatase 2A serves as a scaffolding molecule to coordinate the assembly of the catalytic subunit and a variable regulatory B subunit. Required for proper chromosome segregation and for centromeric localization of SGO1 in mitosis.|
|Cellular Location||Cytoplasm. Chromosome, centromere. Note=Centromeric localization requires the presence of BUB1|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
PPP2R1A is a constant regulatory subunit of protein phosphatase 2. Protein phosphatase 2 is one of the four major Ser/Thr phosphatases, and it is implicated in the negative control of cell growth and division. It consists of a common heteromeric core enzyme, which is composed of a catalytic subunit and a constant regulatory subunit, that associates with a variety of regulatory subunits. The constant regulatory subunit A serves as a scaffolding molecule to coordinate the assembly of the catalytic subunit and a variable regulatory B subunit.
Suzuki, K., et al., Int. J. Oncol. 23(5):1263-1268 (2003).Elder, R.T., et al., Virology 287(2):359-370 (2001).Ruteshouser, E.C., et al., Oncogene 20(16):2050-2054 (2001).Hrimech, M., et al., EMBO J. 19(15):3956-3967 (2000).Zolnierowicz, S., Biochem. Pharmacol. 60(8):1225-1235 (2000).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.